Navigating Payer Decisions in an Evolving Multiple Myeloma Treatment Landscape - Novel Strategies for MM Management and Decision Support Tool

Thursday, September 3, 11am to 11:45am ET

Learn About:

1. Prognostic factors that may enhance prediction of MM patient outcomes
2. MM treatment, including targeted agents in earlier lines of therapy, and the cost of disease progression

Expert Faculty Presenters

Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC, FAPO, FHOPA Director of Pharmacy | Minnesota Oncology Assistant Professor of Pharmacy | Mayo Clinic College of Medicine Associate Editor | JADPRO Click here for biography Susan Wescott, RPh, MBA Executive Lead Clinical Services, Managed Care Mayo Clinic Click here for biography

Target Audience
The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview
As MM progresses to relapsed/refractory MM (RRMM), the selection of an appropriate treatment regimen becomes more complex, requiring an assessment of severity, risk, and prior lines of therapy. Newer agents such as chimeric antigen receptor (CAR) T-cell therapies or bispecific antibody therapies may be indicated. Current treatment guidelines reflect these considerations. However, incorporating appropriate sequences into treatment algorithms and formulary positioning remains challenging for managed care professionals, and emerging agents from the pipeline further complicate assessment. Beyond pharmacotherapy, understanding the total cost of care for various MM treatment options challenges health plan administrators. This activity will help managed care professionals need to understand the factors affecting the cost-effectiveness of MM treatments and the total cost of care to ensure the best patient outcomes while managing health care costs.

Educational Objectives
After completing this activity, participants should be able to demonstrate improved ability to:

• Identify prognostic factors that may enhance prediction of MM patient outcomes and support personalized medicine
• Review the evolving evidence around MM treatment, including targeted agents in earlier lines of therapy, and the cost of disease progression

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Partners designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Partners designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

UAN:JA4008073-9999-26-271-L01-P
Type of Activity: Application

Continuing Nursing Education
MThe maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

DISCLOSURE OF CONFLICTS OF INTEREST
Partners for Advancing Clinical Education (Partners) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to Partners policy. Partners is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.